Today's Research Reports on Trending Tickers: Loxo Oncology and Halozyme Therapeutics
NEW YORK, NY / ACCESSWIRE / November 16, 2018 / U.S. equities regained footing on Thursday as oil prices climbed and hopes of a trade agreement between the U.S. and China raised investor’s optimism. The Dow Jones Industrial Average gained 0.83 percent to close at 25,289.27, while the S&P 500 Index jumped 1.06 percent to close at 2,730.20. The Nasdaq Composite Index rose 1.72 percent at 7,259.03.
According to Ray Dalio, founder of Bridgewater Associates, "The world by and large is leveraged long, when there is a downturn, I don't think there's much to protect investors." "Any investor should have a strategic asset allocation mix. In other words, what will be the neutral portfolio in an overall period of time and then figure out where there is alpha. That will distinguish the winners and the losers" referring to the next bear market, he added.
MER Initiates Coverage on:
Loxo Oncology, Inc.
https://marketedgereport.com/report/LOXO/
Halozyme Therapeutics, Inc.
https://marketedgereport.com/report/HALO/
Loxo Oncology's stock jumped 5.65% Thursday, to close the day at $151.53. The stock recorded a trading volume of 440,854 shares, which was above its three months average volume of 295,656 shares. In the last year, Loxo Oncology's shares have traded in a range of 71.45 - 208.95. The share price has gained 112.08% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $163.02 is below its 200-day moving average of $164.68. Shares of Loxo Oncology have fallen roughly 4.49 percent in the past month and are up 80.01 percent year-to-date.
Access MER's Loxo Oncology, Inc. Research Report at:
https://marketedgereport.com/report/LOXO/
On Thursday, shares of Halozyme Therapeutics recorded a trading volume of 788,189 shares, which was below the three months average volume of 881,596 shares. The stock ended the day 5.74% higher at $16.20. The share price has fallen 24.58% from its 52 week high with a 52 week trading range of 15.03 - 21.48. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $17.51 is below its 200-day moving average of $18.09. Shares of the company are trading at a Price to Earnings ratio of 30.98. Shares of Halozyme Therapeutics have fallen roughly 5.87 percent in the past month and are down 20.04 percent year-to-date.
Access MER's Halozyme Therapeutics, Inc. Research Report at:
https://marketedgereport.com/report/HALO/
Our Actionable Research on Loxo Oncology, Inc. (NASDAQ :LOXO) and Halozyme Therapeutics, Inc. (NASDAQ :HALO) can be downloaded free of charge at MarketEdge Report.
MarketEdge Report
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
MarketEdge has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of MarketEdgeReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketEdgeReport.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.marketedgereport.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
MarketEdge Report, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: MarketEdgeReport.com
